Analyst Expectations for BioXcel Therapeutics's Future
Portfolio Pulse from Benzinga Insights
BioXcel Therapeutics (NASDAQ:BTAI) has received 5 bullish and 3 indifferent analyst ratings in the last quarter. The average price target is $31.25, representing a significant upside from the current price of $4.33. However, this target is a 35.79% decrease from the previous average price target of $48.67.
August 15, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioXcel Therapeutics has received positive analyst ratings, which could potentially drive the stock price up in the short term.
Analyst ratings often influence investor sentiment and can impact stock prices. The bullish ratings and the significant upside implied by the average price target suggest a positive short-term impact on BioXcel Therapeutics' stock.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100